Alpine Immune Sciences, Inc.
Edit

Alpine Immune Sciences, Inc.

https://www.alpineimmunesciences.com/
Last activity: 04.10.2024
Active
Categories: BioTechClinicDevelopmentPlatformProductResearchTechnology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases and cancer, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.
Followers
520
Mentions
13
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $108M
Founded date: 2015
Twitter
LinkedIn

Investors 4

Funding Rounds 2

DateSeriesAmountInvestors
24.07.2020-$60MOmega Fund...
13.06.2016Series A$48MOrbiMed

Mentions in press and media 13

DateTitleDescription
04.10.2024Frazier Life Sciences: Over $630 Million Added To Evergreen Public FundFrazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri...
24.10.2022Alpine stops enrollment in cancer drug study after second patient death this yearA patient has died in a clinical trial testing an experimental Alpine Immune Sciences cancer immunotherapy, the second death in the study this year. The safety issue has prompted the company to stop enrollment in studies of the experimental...
20.09.2022Alpine Immune Sciences Announces Pricing of $100 Million Public Offering-
15.09.2021Three De­mo­c­rat reps op­pose Medicare drug pric­ing plan; Alpine Im­mune an­nounces pri­vate place­mentA trio of key De­moc­rats said yes­ter­day they will op­pose their par­ty’s plan to low­er drug prices — cre­at­ing a sub­stan­tial road­block for the De­moc­rats’ — and the White House’s — de­sired $3.5 tril­lion tax and spend­ing pack­age...
24.05.2019Life sci­ences fund rais­es €118M for its next round of bets; Gilead scraps Alpine al­liance→ A small but grow­ing transat­lantic biotech in­vestor is get­ting a fresh shot in the arm for its next round of bets. Foun­tain Health­care Part­ners has raised €118 mil­lion for Fund III, bring­ing its to­tal amount of cap­i­tal raised t...
01.02.2019Seattle Venture Capital Watch: Alpine Immune, Wyze, Aduro, Gaia & MoreShare Share on Facebook Share on Twitter LinkedIn Email Reprints Welcome to February! Whether your weekend plans involve watching the Super Bowl, tracking this year’s prediction by famed groundhog Punxsutawney Phil, or other activities, tak...
18.04.2017Ex-Den­dreon chief Mitch Gold steers his way back to the pub­lic mar­kets, look­ing to jump­start a new clin­i­cal pro­gramMitch Gold is com­ing back to the helm of a pub­lic biotech com­pa­ny. The for­mer Den­dreon CEO — and cur­rent ven­ture cap­i­tal­ist — who was forced out of that com­pa­ny as Provenge slow­ly de­railed, is get­ting back in­to the pub­lic ...
13.06.2016Alpine Immune Sciences Closes $48M Series A Financing RoundAlpine Immune Sciences, Inc., a Seattle, WA-based biotechnology company developing an immune system modulation platform, closed a $48m Series A financing round. The round was led by OrbiMed Advisors, with participation from Frazier Healthca...
13.06.2016OrbiMed Leads $48M Series A for Alpine Immune SciencesSEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next-generation immune system modulation platform, today announced the closing of its $48 million Series A financing round. T...
13.06.2016OrbiMed Leads $48M Series A for Alpine Immune SciencesSEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next-generation immune system modulation platform, today announced the closing of its $48 million Series A financing round. T...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In